Based on the expanded source material, which now details **Data Mapping**, **Fuzzy Matching**, **Master Data Management (MDM)**, and **Molecular Pharmacology**, here are additional data visualizations tailored for the PPN (Physicians Private Network) React application.  
These examples focus on the "back-office" data integrity required for a robust registry, as well as the "hard science" molecular comparisons requested in the meeting notes.

### **1\. The "Golden Record" Entity Resolution Workspace**

**Type:** Side-by-Side Comparison with Confidence Gauge**Level:** Admin / Data Steward (Network Level)  
**Description:**The sources emphasize that real-world data is messy (e.g., "Jon Smith" vs. "John Smith") and requires **Fuzzy Matching** algorithms (Levenshtein, Jaro-Winkler) to identify duplicates without violating HIPAA 1, 2\. This visualization allows a Data Steward to resolve identity conflicts to create a "Golden Record" 3, 4\. It displays two potential patient records side-by-side with a probabilistic match score, allowing the user to "Merge" or "Reject".  
**Sample Source Data (Incoming Stream vs. Master Database):**Derived from PATIENTS\_REGISTRY and incoming CSV imports.  
Field,Master Record (PT-8832),Incoming Record (Import),Match Score,Algorithm Used  
Name,Encrypted,Encrypted,92%,Jaro-Winkler 5  
DOB,1985-01-01,1985-01-01,100%,Exact Match 5  
Phone,555-0199,555-019-9,95%,Numeric Token 6  
Email,j.doe@email.com,john.doe@email.com,85%,Levenshtein 5  
Overall,Likely Match,,91%,Weighted Avg  
**Practical Application:**Before aggregating data for research, the system must ensure that a patient visited three different clinics is counted as *one* person, not three. This tool visualizes the "Probabilistic Matching" process 7, preventing data fragmentation and ensuring the integrity of the "Real-World Evidence" (RWE).  
**React Implementation:**

* **Library:** Custom UI using Material UI cards or React-Diff-View concepts.  
* **Visuals:** Use a central "Gauge" chart (e.g., react-gauge-chart) to show the 91% confidence score. Green \= Auto-Merge range (\>90%), Yellow \= Manual Review (75-89%) 8\.  
* **Action:** "Merge" buttons that trigger an API call to update the USUBJID link in the PATIENTS\_REGISTRY table 9\.

### **2\. Pharmacological "Fingerprint" Radar Chart**

**Type:** Radar / Spider Chart**Level:** Clinical / Research (Aggregate & Individual)  
**Description:**Meeting notes request "chemical drill down" capabilities where hovering over a receptor (e.g., 5-HT2A) explains its function 10\. This visualization compares the **Binding Affinity ($K\_i$)** of different psychedelic substances against specific neuroreceptors. It allows clinicians to visualize why LSD might induce more anxiety (due to dopaminergic activity) compared to Psilocybin.  
**Sample Source Data:**Derived from substances\_ref joined with external molecular datasets (e.g., NIMH-PDSP) 11, 12\. Values are inverted ($1/K\_i$) so *larger* spikes indicate *stronger* binding.  
Receptor,Psilocin (Active),LSD,MDMA,Function 10  
5-HT2A,0.93,28.5,0.1,Psychedelic visual effects  
5-HT1A,0.2,3.1,0.5,Mood/Anxiety regulation  
5-HT2B,21.0,3.3,0.8,Cardiac valvulopathy risk  
D2 (Dopamine),0.01,4.2,0.2,Stimulant/Euphorigenic  
Adrenergic,0.05,1.5,1.2,Physical arousal/HR  
**Practical Application:**A clinician treating a patient with a heart condition can look at the "5-HT2B" axis. Seeing the high spike for Psilocin vs. LSD might prompt them to monitor cardiac markers more closely or choose a different compound, directly supporting the "Safety Partner" value proposition 13\.  
**React Implementation:**

* **Library:** Recharts or Nivo Radar Chart.  
* **Interaction:** Implement a CustomTooltip that reveals the "Receptor Function" (e.g., "Regulates Mood") when hovering over a specific axis point 10\.  
* **Data Mapping:** Map RxNorm\_CUI (e.g., 1433 for Psilocybin) to the molecular data JSON file from Kaggle/PDSP 14\.

### **3\. The "What Went Wrong" Pareto Chart**

**Type:** Pareto Chart (Bar \+ Line)**Level:** Global Network / Aggregate  
**Description:**The sources highlight the unique value of capturing "Failure Data" and "what went wrong," which is often missing from standard trials 15\. A Pareto chart highlights the "Vital Few" adverse events that account for the majority of issues. This helps practitioners prioritize which risks to discuss during informed consent.  
**Sample Source Data:**Aggregated from SAFETY\_EVENTS table 16\.  
Adverse Event (MedDRA),Count (Bar),Cumulative % (Line),Severity Avg (1-4)  
Nausea (10028813),450,45%,1.5 (Mild)  
Anxiety (10002855),300,75%,2.5 (Moderate)  
Headache (10019211),150,90%,1.2 (Mild)  
Tachycardia (10043071),50,95%,1.8 (Mild)  
Psychosis,5,99%,4.0 (Severe)  
**Practical Application:**This visualization instantly validates the "Safety" value prop. If a clinic sees a spike in "Tachycardia" that deviates from the global Pareto curve, they know they have an anomaly (e.g., a batch issue or protocol error).  
**React Implementation:**

* **Library:** Recharts ComposedChart (Bar \+ Line).  
* **Configuration:** The Bar chart plots Count (frequency). The Line chart plots Cumulative %.  
* **Drill-Down:** Clicking the "Nausea" bar should filter the INTERVENTIONS\_LOG to show which specific Substance\_Name or Route\_SNOMED (e.g., Oral vs. IV) is driving that specific adverse event 17\.

### **4\. Patient Demographics & Response Clustering**

**Type:** Scatter Plot with Cluster Zones**Level:** Aggregate Research  
**Description:**The NSIHT survey data indicates usage trends vary significantly by age and region 18\. This visualization plots patients by **Age** (X-axis) and **Symptom Reduction** (Y-axis), colored by **Substance**. It visually identifies "Responders" vs. "Non-Responders" across demographics.  
**Sample Source Data:**Joined PATIENTS\_REGISTRY and OUTCOMES\_ASSESSMENT.  
Patient\_ID,Age (Derived ISO),Outcome Delta (PHQ-9),Substance,Cluster  
PT-101,24,-15 (High Response),Psilocybin,Young/High  
PT-102,55,-2 (Low Response),Ketamine,Older/Low  
PT-103,28,-12 (High Response),MDMA,Young/High  
PT-104,45,-5 (Med Response),Ketamine,Mid/Med  
**Practical Application:**A researcher can visually spot that "Younger adults" (Left side of chart) might be responding better to Psilocybin, while "Older adults" might show better clusters around Ketamine. This supports the "Transdiagnostic" modeling mentioned in the clinical analysis sources 19\.  
**React Implementation:**

* **Library:** Victory or Recharts Scatter.  
* **Logic:** Calculate Age dynamically from Birth\_Date\_ISO 9 to ensure the data remains live.  
* **Filter:** Allow toggling Sex\_Code (M/F) or Condition\_Code (e.g., PTSD vs. TRD) to see if the clusters shift, helping to identify high-risk subgroups like those with Personality Disorders 20\.

